CD152 Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “CD152 Inhibitor The report assesses the active CD152 Inhibitor ...
January 2022
60 pages
CD40 Agonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “CD40 Agonist The report assesses the active CD40 Agonist pipeline ...
January 2022
60 pages
Cell Division Cycle 7 (CDC7) Related Protein Kinase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cell Division Cycle 7 (CDC7) Related Protein Kinase Inhibitor ...
January 2022
60 pages
Cell wall inhibitors - Pipeline Insight, 2022
US$ 2,000.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cell Wall Synthesis Inhibitor The report assesses ...
January 2022
60 pages
cFMS Kinase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “cFMS Kinase Inhibitor The report assesses the active cFMS Kinase ...
January 2022
60 pages
Checkpoint Kinase Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Checkpoint Kinase Inhibitor The report assesses ...
January 2022
90 pages
Checkpoint Kinase 1 (Chk1) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Checkpoint Kinase 1 (Chk1) Inhibitor The report ...
January 2022
60 pages
Checkpoint Kinase 2 (Chk2) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Checkpoint Kinase 2 (Chk2) Inhibitor The report ...
January 2022
60 pages
Chemokine Receptor Antagonist - Pipeline Insight, 2022
US$ 2,000.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Chemokine Receptor Antagonist The report assesses ...
January 2022
120 pages
Cholecystokinin Receptor (CCK) Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cholecystokinin Receptor (CCK) Antagonist The report ...
January 2022
60 pages
Cholesterol Absorption Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cholesterol Absorption Inhibitor The report ...
January 2022
60 pages
Cholesterylester Transfer Protein (CETP) Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cholesterylester Transfer Protein (CETP) Inhibitor The ...
January 2022
90 pages
CRF1 Receptor Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “CRF1 Receptor Antagonist The report assesses ...
January 2022
60 pages
CXCR4 Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “CXCR4 Inhibitor The report assesses the active CXCR4 Inhibitor ...
January 2022
90 pages
Cyclin-Dependent Kinase 1 (CDK1) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cyclin-Dependent Kinase 1 (CDK1) Inhibitor The report ...
January 2022
60 pages
Cyclin-Dependent Kinase 2 (CDK2) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cyclin-Dependent Kinase 2 (CDK2) Inhibitor The report ...
January 2022
60 pages
Cyclin-Dependent Kinase 6/4 (CDK6/4) Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cyclin-Dependent Kinase 6/4 (CDK6/4) Inhibitor The ...
January 2022
90 pages
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cyclin-Dependent Kinase 9 (CDK9) Inhibitor The report ...
January 2022
90 pages
Cyclophilin Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cyclophilin Inhibitor The report assesses ...
January 2022
60 pages
Cystic Fibrosis Transmembrane Conductance Regulators (CFTR) - Pipeline Insight, 2022
US$ 1,500.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cystic Fibrosis Transmembrane Conductance Regulators (CFTR) The ...
January 2022
90 pages
Cytochrome P450 Superfamily (CYP or CYP450) Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cytochrome P450 Superfamily (CYP or CYP450) Inhibitor The ...
January 2022
90 pages
Cytochrome P450 17 (CYP17) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cytochrome P450 17 (CYP17) Inhibitor The report ...
January 2022
60 pages
D Agonist - Pipeline Insight, 2022
US$ 2,000.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D Agonist The report assesses the active D Agonist pipeline ...
January 2022
120 pages
D Antagonist - Pipeline Insight, 2022
US$ 1,500.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D Antagonist The report assesses the active D Antagonist pipeline ...
January 2022
90 pages
D1 Agonist - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D1 Agonist The report assesses the active D1 Agonist pipeline ...
January 2022
60 pages
D1 Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D1 Antagonist The report assesses the active D1 Antagonist pipeline ...
January 2022
60 pages
D2 Agonist - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D2 Agonist The report assesses the active D2 Agonist pipeline ...
January 2022
60 pages
D3 Agonist - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D3 Agonist The report assesses the active D3 Agonist pipeline ...
January 2022
60 pages
D3 Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D3 Antagonist The report assesses the active D3 Antagonist pipeline ...
January 2022
60 pages
D4 Agonist - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D4 Agonist The report assesses the active D4 Agonist pipeline ...
January 2022
60 pages
D4 Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D4 Antagonist The report assesses the active D4 Antagonist pipeline ...
January 2022
60 pages
Delta Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Delta Antagonist The report assesses the active Delta Antagonist ...
January 2022
60 pages
Diglyceride Acyltransferase (DGAT) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Diglyceride Acyltransferase (DGAT) Inhibitor The report ...
January 2022
60 pages
Dihydroorotate dehydrogenase inhibitors - Pipeline Insight, 2022
US$ 1,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Dihydroorotate Dehydrogenase (DHODH) Inhibitor The ...
January 2022
60 pages
DNA Methyltransferase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “DNA Methyltransferase Inhibitor The report assesses the active DNA ...
January 2022
60 pages
DNA-Dependent RNA Polymerase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “DNA-Dependent RNA Polymerase Inhibitor The report ...
January 2022
60 pages
Dopaminergic Agonist - Pipeline Insight, 2022
US$ 2,000.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Dopaminergic Agonist The report assesses ...
January 2022
120 pages
Dopaminergic system Antagonist - Pipeline Insight, 2022
US$ 2,000.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Dopaminergic system Antagonist The report assesses ...
January 2022
120 pages
Prostaglandin D2 receptor Antagonist - Pipeline Insight, 2022
US$ 1,500.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “DP1 Receptor (Prostaglandin D2 receptor) Antagonist The ...
January 2022
60 pages
Eg5 Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Eg5 Inhibitor The report assesses the active Eg5 Inhibitor pipeline ...
January 2022
60 pages
Elastase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Elastase Inhibitor ...
January 2022
60 pages
Endothelin Receptor Antagonist - Pipeline Insight, 2022
US$ 1,500.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Endothelin Receptor (ET) Antagonist The report ...
January 2022
60 pages
Endothelin Receptor A (ETA) Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Endothelin Receptor A (ETA) Antagonist The report ...
January 2022
60 pages
Enhancer of zeste homolog 2 (EZH2) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Enhancer of zeste homolog 2 (EZH2) Inhibitor The report ...
January 2022
60 pages
Ephrin (EPH) Receptor Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Ephrin (EPH) Receptor Antagonist The report ...
January 2022
60 pages
Ephrin Type A Receptor 2 (EPH Receptor A2 or EPHA2) Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Ephrin Type A Receptor 2 (EPH Receptor A2 or EPHA2) Antagonist ...
January 2022
60 pages
Epithelial Sodium Channel (ENaC) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Epithelial Sodium Channel (ENaC) Inhibitor The report ...
January 2022
60 pages
Estrogen Receptor Beta Partial Agonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Estrogen Receptor Beta Partial Agonist The report ...
January 2022
60 pages
